Literature DB >> 22803318

Colorectal cancer screening in LHU4 Chiavarese, Italy: ethical, methodological and outcome evaluations at the end of the first round.

M Ferrari Bravo1, V De Conca, G L Devoto, M Sironi, R Mele, A Fumagalli, P Rimassa, G Rossi, A Zampogna, C Sticchi, G Gabutti.   

Abstract

UNLABELLED: INTRODUCTION. The screening programmes are very challenging from the ethical perspective, and their impact in terms of morbidity and mortality make secondary colorectal cancer prevention a valuable public health intervention.
METHODS: The target population people aged 50-69 years receive an invitation card with a test-tube for the fecal occult blood test (FOBT) and an immunochemical test is used for fecal occult blood. Subjects positive to FOBT are invited to perform a gastroenterologic examination and a full colonoscopy.
RESULTS: In the firt round of screening, 100% of the target population has been invited with an adhesion rate of 41.3%. A total of 1739 FOBT-positive subjects have been invited to the second level of the screening. 1429 of them have performed the gastroenterologic examination (83.9%). To date 956 full colonoscopies have been completed and the rate of subjects affected by carcinoma, malignant polyp and advanced adenoma has been equal to 23.5%. DISCUSSION: Thanks to the reminders already sent, an increasing compliance has been registered with an increased rate of subjects with a low schooling that have performed a FOBT test. With the aim to optimize all the operative aspects of the screening programme it is already ongoing a set of meetings between health workers of Local Health Unit 4 and General Practioners.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22803318

Source DB:  PubMed          Journal:  J Prev Med Hyg        ISSN: 1121-2233


  1 in total

1.  The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.

Authors:  Rachel Gingold-Belfer; Haim Leibovitzh; Doron Boltin; Nidal Issa; Tsachi Tsadok Perets; Ram Dickman; Yaron Niv
Journal:  United European Gastroenterol J       Date:  2019-02-06       Impact factor: 4.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.